📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
6 analysed today
FollowTelegram
6
Today
151,868
All-time analysed
43,540
Positive
6,743
Negative
92,748
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
846 announcements match the current filters (relevance ≥ 5).
Biocon Receives US FDA EIR with VAI Status for New Jersey Generics Facility
Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Cranbury, New Jersey facility.
The inspection was conducted over a 5-day period from October 6 to October 10, 2025.
The facility received a 'Voluntary Action Indicated' (VAI) classification, avoiding more severe regulatory sanctions.
The EIR marks the formal closure of the inspection cycle for this specific U.S.-based manufacturing site.
👀 What to Watch
Investors should view this as a positive regulatory development that reduces compliance risk for Biocon's U.S. operations. This clearance supports the company's ability to maintain supply and seek new product approvals from this facility.
A B Infrabuild Secures ₹52.08 Crore Railway Project for Road Over Bridge Construction
A B Infrabuild Limited has received a Letter of Acceptance from East Coast Railways for a significant infrastructure project. The contract involves the construction of a Road Over Bridge (ROB) on the HWH-VSKP main line under the Khurdha Road division. Valued at approximately ₹52.08 Crores, the project is scheduled to be completed within a 24-month timeframe. This order strengthens the company's presence in the railway infrastructure sector and adds to its revenue visibility.
Key Highlights
Awarded a domestic contract worth ₹52,08,33,449.63 from East Coast Railways.
Project involves construction of a Road Over Bridge (ROB) with composite and T-Beam girders.
The execution period for the entire project is set at 24 months.
The contract was secured through a competitive tender process with no promoter interest involved.
👀 What to Watch
Investors should view this as a positive development for the company's order book and monitor the execution progress over the next 24 months. The company's ability to secure and deliver on Indian Railways projects is a key driver for its long-term valuation.
Bigbloc Construction H1 FY26: Capacity Hits 1.3M CBM; 5-Year Revenue CAGR at 21.5%
Bigbloc Construction has successfully expanded its AAC block capacity to 1.3 million CBM per annum, achieving a 21.5% revenue CAGR over the last five years. The company reported FY25 revenue of INR 2,246 million and is diversifying into construction chemicals and wall panels via a JV with Thailand's SCG International. Despite lower FY25 return ratios (ROE 2.1%) due to heavy expansion capex, the company maintains a competitive <2% rejection rate and generates carbon credits. Future growth is anchored by a new greenfield project in Madhya Pradesh and potential entry into South Indian markets.
Key Highlights
Total manufacturing capacity increased to 13,00,000 CBM P.A. as of FY2025 from 5,75,000 in FY2022.
Maintained a 5-year Revenue CAGR of 21.5% and EBITDA CAGR of 24.6% as of FY2025.
Operational efficiency highlighted by a rejection rate of <2% compared to the 4-7% industry average.
Strategic JV with SCG International for AAC wall panels and expansion into construction chemicals like tile adhesives.
Planned greenfield expansion in Madhya Pradesh with 200,000 CBM capacity, expandable to 500,000 CBM.
👀 What to Watch
Investors should monitor the capacity utilization of the newly commissioned Wada and Ramosadi plants and the scale-up of the high-margin construction chemicals segment. The company is a strong play on green building materials, though current return ratios reflect a heavy investment phase.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Experience
Concord Biotech has appointed Mr. Raviraj Karia as its new Chief Financial Officer, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Intas Pharmaceuticals and Claris Lifesciences. His expertise spans multi-billion dollar financing, large-scale M&A, and cost-efficiency programs. This strategic appointment is aimed at strengthening the company's financial discipline and governance as it scales.
Key Highlights
Appointment of Mr. Raviraj Karia as CFO and Key Managerial Personnel effective December 18, 2025
Brings over 23 years of experience in pharmaceuticals, healthcare, and private equity sectors
Previously managed multi-billion dollar financing programs and led major outbound pharma acquisitions
Proven track record of reducing borrowing costs by 2-3% annually through financial optimization
Expertise in implementing digital tools like SAP-based MIS and Power BI for financial governance
👀 What to Watch
Investors should view this as a positive move for corporate governance and financial strategy. Monitor the company's future capital allocation and cost-efficiency metrics under the new leadership.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Finance Experience
Concord Biotech Limited has appointed Mr. Raviraj Karia as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of extensive experience in the pharmaceutical, healthcare, and clinical research sectors. He has previously held leadership roles at prominent firms such as Intas Pharmaceuticals, Claris Lifesciences, and Shalby Hospitals. His expertise includes managing multi-billion dollar financing programs and executing large-scale outbound acquisitions, which is expected to strengthen the company's financial governance.
Key Highlights
Mr. Raviraj Karia appointed as CFO and Key Managerial Personnel effective December 18, 2025.
Brings over 23 years of experience across pharmaceuticals, healthcare, and private equity sectors.
Proven track record in managing multi-billion dollar financing and reducing borrowing costs by 2-3% annually in previous roles.
Expertise in M&A, having led India’s largest outbound pharma acquisition during his career.
Previous leadership experience at Intas Pharmaceuticals, Sakar Healthcare, and Lambda Therapeutics.
👀 What to Watch
Investors should view this as a positive step in strengthening the leadership team; monitor the company's financial strategy and capital allocation under the new CFO.
MobiKwik Appoints Navdeep Singh Suri as Board Chair; Separates Chair and Executive Roles
One MobiKwik Systems has appointed Navdeep Singh Suri, an Independent Director since 2021 and former diplomat, as the new Chairperson of its Board. This strategic move separates the Chairperson's role from executive management, as he succeeds Co-Founder and CFO Upasana Taku. The company currently commands a 19% market share in India's PPI wallet gross transaction value (GTV) as of September 2025. With a massive base of 183.5 million registered users and 4.71 million merchants, this transition is aimed at enhancing corporate governance and institutional maturity.
Key Highlights
Navdeep Singh Suri appointed as Board Chairperson, having served as an Independent Director since 2021.
The appointment separates the Board Chair role from executive management, succeeding Co-Founder Upasana Taku.
MobiKwik holds a 19% market share of the PPI wallet gross transaction value (GTV) as of September 2025.
The company reports a user base of over 183.5 million registered users and 4.71 million merchants.
Mr. Suri brings extensive governance experience from the Indian Foreign Service and roles at SBI Funds International.
👀 What to Watch
Investors should view this as a positive governance milestone that aligns the company with global best practices by separating board oversight from executive functions. Monitor the company's ability to leverage this institutional maturity to further scale its 19% market share in the digital wallet space.
SBI Extends Tenure of Managing Director Ashwini Kumar Tewari Until December 2027
The Government of India has officially re-appointed Shri Ashwini Kumar Tewari as the Managing Director of State Bank of India. His current term was scheduled to conclude on January 27, 2026. The new extension ensures his leadership continues until his superannuation on December 31, 2027, or until further orders. This move provides significant leadership continuity for India's largest public sector lender during a critical period of credit growth.
Key Highlights
Shri Ashwini Kumar Tewari re-appointed as Managing Director of State Bank of India
Extension granted beyond the current term ending January 27, 2026
New tenure valid until superannuation date of December 31, 2027
Notification issued by the Department of Financial Services, Ministry of Finance
👀 What to Watch
Investors should welcome this continuity in top management as it ensures stability in the bank's strategic direction. No immediate portfolio changes are necessary based on this administrative update.
MobiKwik Appoints Former SEBI ED Radhakrishna Nair to Board; Navdeep Singh Suri Named Chairperson
One Mobikwik Systems Limited has announced a significant strengthening of its board governance by appointing Mr. Radhakrishna Nair as an Independent Director for a five-year term. Mr. Nair brings over 40 years of experience, including senior regulatory roles as Executive Director at SEBI and Member at IRDAI. Additionally, the company has appointed Independent Director Mr. Navdeep Singh Suri as the Chairperson of the Board, replacing co-founder Ms. Upasana Rupkrishan Taku. These moves indicate a strategic shift toward professionalizing board leadership and enhancing regulatory oversight.
Key Highlights
Mr. Radhakrishna Nair appointed as Additional Director (Independent) for a 5-year term until December 16, 2030.
Mr. Navdeep Singh Suri, an Independent Director, replaces co-founder Ms. Upasana Rupkrishan Taku as Board Chairperson.
Mr. Nair possesses over 40 years of experience in banking and served as Executive Director at SEBI and Member at IRDAI.
The Board has approved a Postal Ballot to seek shareholder approval for the new Independent Director appointment.
👀 What to Watch
Investors should view the addition of a former SEBI and IRDAI official as a positive step for a fintech company navigating complex regulatory landscapes. The transition to an Independent Chairperson further strengthens corporate governance standards.
Biocon Retains [ICRA]AA+ Rating; To Acquire BBL Minority Stakes for $1.17 Billion
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash payment, making BBL a wholly-owned subsidiary. To fund the cash component and repay existing structured debt, Biocon plans a QIP of up to Rs. 4,500 crore. This restructuring aims to simplify the group's corporate structure and consolidate BBL, which contributed 58% of consolidated revenues in FY2025.
Key Highlights
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated instruments.
Acquisition of minority stakes in BBL valued at $1.17 billion from Mylan, Serum Institute, and others.
Funding includes a share swap of 171.3 million shares and $400 million cash funded via CP and a Rs. 4,500 crore QIP.
BBL is the largest revenue contributor, accounting for 58% of Biocon's consolidated revenue in FY2025.
Structured debt from the Viatris acquisition is scheduled to be repaid by January 31, 2026, using QIP proceeds.
👀 What to Watch
Investors should monitor the successful execution and pricing of the Rs. 4,500 crore QIP, as it is critical for the company's deleveraging and the BBL consolidation. The move is a long-term positive as it simplifies the corporate structure and eliminates the holding company discount.
ICRA Reaffirms Biocon's AA+ Rating; Highlights $1.17B Biocon Biologics Consolidation
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.
Key Highlights
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated limits.
Biocon to acquire minority stakes in Biocon Biologics for $1.17 billion, making it a 100% subsidiary.
Funding includes a Rs. 6,950 crore share swap and a $400 million cash payment.
Company plans a QIP of up to Rs. 4,500 crore to repay bridge financing and structured debt by Jan 2026.
Biocon Biologics is the largest revenue contributor, accounting for 58% of consolidated FY25 revenue.
👀 What to Watch
Investors should monitor the successful completion of the Rs. 4,500 crore QIP as it is crucial for deleveraging the balance sheet. The consolidation of the biologics business is a strategic positive that eliminates holding company discounts and simplifies the corporate structure.
BIL Vyapar Ltd (Binani Industries) Schedules Committee of Creditors Meeting for Dec 19, 2025
BIL Vyapar Limited, formerly known as Binani Industries Limited, has scheduled a meeting of its Committee of Creditors (CoC) for December 19, 2025. This follows the initiation of the Corporate Insolvency Resolution Process (CIRP) by the NCLT via an order dated November 13, 2025. The company's management and assets are currently under the control of Interim Resolution Professional (IRP) Subodh Kumar Agrawal. This meeting is a critical step in the insolvency process to determine the company's future resolution or liquidation path.
Key Highlights
Committee of Creditors (CoC) meeting scheduled for December 19, 2025
Company placed under Corporate Insolvency Resolution Process (CIRP) effective November 13, 2025
Affairs and assets are being managed by IRP Subodh Kumar Agrawal (Reg No: IBBI/IPA-001/IP-P00087/2017-18/10183)
Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015
NCLT order for insolvency was received by the company on November 21, 2025
👀 What to Watch
Investors should exercise extreme caution as equity value is typically significantly diluted or wiped out during insolvency proceedings. Monitor the CoC meeting outcomes for any proposed resolution plans or potential liquidation updates.
SBI Appoints Ravi Ranjan as Managing Director Effective Dec 15, 2025
State Bank of India (SBIN) announced the appointment of Shri Ravi Ranjan as Managing Director, effective December 15, 2025. He will hold the position until his superannuation on September 30, 2028, or until further orders. Shri Ranjan was previously Deputy Managing Director and is responsible for Risk, Compliance, & Stressed Assets Resolution Group. He joined the bank as Probationary Officer in 1991 and has over 34 years of experience.
Key Highlights
Shri Ravi Ranjan appointed as Managing Director effective December 15, 2025.
Term of appointment is until September 30, 2028 (superannuation) or until further orders.
Shri Ravi Ranjan has over 34 years of experience in banking and finance since 1991.
👀 What to Watch
Investors should note the change in leadership and monitor Shri Ranjan's strategic initiatives in Risk, Compliance, and Stressed Assets Resolution. No immediate action is required.
Panacea Biotec: CFO Appointment, Company Secretary Change & Policy Revision
Panacea Biotec has announced key management changes. Mr. Vinod Goel, currently Group CFO, is appointed as CFO effective December 16, 2025, succeeding Mr. Devender Gupta. Consequently, Mr. Goel will cease to be the Company Secretary. Mr. Ankit Jain is appointed as Company Secretary and Compliance Officer from December 16, 2025. The board also adopted a revised policy for determining the Materiality of Events.
Key Highlights
Mr. Vinod Goel appointed as Group Chief Financial Officer and Head Legal & Corporate Governance w.e.f. December 16, 2025.
Mr. Ankit Jain appointed as General Manager – Legal & Company Secretary w.e.f. December 16, 2025.
Mr. Vinod Goel has over 35 years of post-qualification experience.
Mr. Ankit Jain has around 15 years of experience in corporate governance and regulatory compliance.
Revised Policy for determining Materiality of Events / Information effective December 16, 2025.
👀 What to Watch
Investors should note the changes in key management personnel. Monitor future filings for any impact from the revised policy on materiality of events.
Panacea Biotec appoints Ankit Jain as Company Secretary w.e.f. Dec 16, 2025
Panacea Biotec Limited announced the appointment of Mr. Ankit Jain as the Company Secretary & Compliance Officer, effective December 16, 2025. This follows the cessation of Mr. Vinod Goel from the role of Company Secretary and Compliance Officer on December 15, 2025, due to his appointment as Group CFO. Mr. Jain, aged about 38 years, previously served as Assistant General Manager - Legal of the company’s wholly owned subsidiary, Panacea Biotec Pharma Ltd. The board also revised the policy for determining materiality of events and authorized key managerial personnel for disclosures.
Key Highlights
Ankit Jain appointed as Company Secretary & Compliance Officer w.e.f. December 16, 2025
Vinod Goel appointed as Group CFO and Head Legal & Corporate Governance w.e.f. December 16, 2025
Vinod Goel ceases to be Company Secretary and Compliance Officer w.e.f. December 15, 2025
Ankit Jain has around 15 years of experience in corporate governance
Board meeting concluded at 03:36 P.M. on December 15, 2025
👀 What to Watch
Investors should monitor the company's filings and announcements for further updates on key managerial personnel changes and strategic direction. No immediate action is required.
Panacea Biotec Appoints Vinod Goel as Group CFO and Ankit Jain as Company Secretary
Panacea Biotec Limited has announced a restructuring of its Key Managerial Personnel (KMP) effective December 16, 2025. Following the resignation of CFO Devender Gupta, the company has elevated Mr. Vinod Goel, a veteran with the firm since 1999, to the position of Group Chief Financial Officer. Simultaneously, Mr. Ankit Jain, who has 15 years of experience and was previously with the company's subsidiary, has been appointed as the new Company Secretary and Compliance Officer. These internal transitions aim to ensure leadership continuity and stable corporate governance.
Key Highlights
Mr. Vinod Goel appointed as Group CFO and Head Legal & Corporate Governance effective December 16, 2025.
Mr. Ankit Jain appointed as Company Secretary and Compliance Officer effective December 16, 2025.
Outgoing CFO Mr. Devender Gupta's resignation is effective from December 15, 2025.
Mr. Vinod Goel brings over 35 years of experience and has been with Panacea Biotec for approximately 26 years.
The Board updated its policy for determining materiality and authorized 7 KMPs for regulatory disclosures.
👀 What to Watch
No immediate action is required as the appointments represent an internal succession plan, which typically suggests stability in financial and legal operations.
Panacea Biotec appoints Vinod Goel as CFO, effective Dec 16, 2025
Panacea Biotec has appointed Mr. Vinod Goel as the Chief Financial Officer (CFO) with effect from December 16, 2025. Mr. Goel, who is currently the Group CFO and Head Legal & Company Secretary, will now be designated as Group Chief Financial Officer and Head Legal & Corporate Governance. This follows the resignation of Mr. Devender Gupta from the CFO position, effective December 15, 2025. Mr. Ankit Jain has been appointed as Company Secretary and Compliance Officer with effect from December 16, 2025.
Key Highlights
Mr. Vinod Goel appointed as CFO w.e.f. December 16, 2025
Mr. Ankit Jain appointed as Company Secretary w.e.f. December 16, 2025
Mr. Vinod Goel has over 35 years of post-qualification experience
Mr. Ankit Jain has around 15 years of experience
👀 What to Watch
The appointment of a new CFO and Company Secretary is a routine management change. Investors should monitor the company's performance under the new leadership.
SBI to sign EURO 150 million Line of Credit with KfW
State Bank of India (SBI) will be signing a EURO 150 million Line of Credit with KfW (German Development bank). This credit line is dedicated to financing Climate Friendly Energy Generation projects. The signing is scheduled for December 16, 2025, at KfW Headquarters Frankfurt. This initiative indicates SBI's commitment to sustainable financing and could enhance its reputation among environmentally conscious investors.
Key Highlights
SBI to sign EURO 150 million Line of Credit with KfW
Line of Credit is for financing Climate Friendly Energy Generation projects
Signing scheduled on 16.12.2025 at KfW Headquarters Frankfurt
👀 What to Watch
Investors should note SBI's increasing focus on green financing, which could positively impact its long-term sustainability and attract ESG-focused investments. Monitor the deployment and impact of this EURO 150 million credit line on SBI's financials and environmental footprint.
MobiKwik Q2 FY26: EBITDA Losses Narrow by 80% QoQ; Contribution Profit Up 24%
One MobiKwik Systems Limited reported a strong operational recovery in Q2 FY26, with EBITDA losses narrowing significantly to INR 64 Mn from INR 312 Mn in Q1 FY26. While total income remained steady at INR 2,793 Mn, contribution profit rose 24% QoQ to INR 961 Mn, driven by a 10% reduction in direct costs and a 5.7% reduction in fixed costs. The payments business achieved a record GMV of INR 432 Bn (up 53% YoY), and financial services gross margins rebounded sharply to 41.8% from 13.3% in the previous quarter.
Key Highlights
EBITDA loss narrowed by 80% QoQ to INR 64 Mn, moving the company closer to breakeven.
Payments GMV grew 53% YoY to reach a record INR 432 Bn in Q2 FY26.
Financial Services Gross Margin surged to 41.8% from 13.3% QoQ as lending costs normalized.
Registered user base reached 183.5 Mn, reflecting a 9.9% YoY growth with 3.3 Mn new users added in Q2.
Direct costs were optimized by 10% QoQ, while fixed costs decreased by 5.7% to INR 1,025 Mn.
👀 What to Watch
Investors should view the sharp reduction in EBITDA losses and the recovery in financial services margins as a positive sign of the company's path to profitability. Monitor the sustainability of cost-cutting measures and the growth of the UPI and FX Retail segments in upcoming quarters.
MobiKwik Q2 FY26: EBITDA Loss Narrows 80% QoQ to ₹6.4 Cr; UPI GMV Grows 3.5x YoY
One MobiKwik Systems Limited demonstrated a strong operational turnaround in Q2 FY26, with EBITDA losses narrowing significantly from ₹31.2 Cr to ₹6.4 Cr, an 80% QoQ improvement. The company's UPI GMV saw explosive growth of 3.5x YoY, reaching ₹138.26 Bn, while total Payments GMV rose 53% YoY to ₹432 Bn. Financial Services margins rebounded sharply to 41.8% from 13.3% in the previous quarter, driven by a 29% reduction in lending-related expenses. With a registered user base of 183.5 Mn and a 24% QoQ increase in contribution profit, the company is nearing its breakeven milestone.
Key Highlights
EBITDA loss narrowed by 80% QoQ to ₹64 Mn, reflecting strong operating efficiency and cost discipline.
UPI GMV witnessed 3.5x YoY growth, reaching ₹138.26 Bn, making it one of the fastest-growing UPI apps.
Financial Services Gross Margin jumped to 41.8% from 13.3% QoQ, resulting in an INR 179 Mn gain in gross profit.
Contribution Profit increased by 24% QoQ to ₹961 Mn, with contribution margins expanding to 34.4%.
Registered user base reached 183.5 Mn, with 3.3 Mn new users and 71k new merchants added in Q2 FY26.
👀 What to Watch
Investors should closely monitor the company's trajectory toward EBITDA breakeven in Q3 FY26 and the successful scaling of its new FX Retail and Digital Rupee initiatives.
Aditya Birla Money Extends Preference Share Redemption to 2026; Total Value ₹109.99 Cr
Aditya Birla Money has approved a one-year extension for the redemption of 16,00,000 preference shares held by its promoter, Aditya Birla Capital. The redemption date is moved from December 2025 to December 2026, providing short-term liquidity relief. However, the redemption price per share has been increased from ₹639 to ₹687.44 to compensate for the delay. This adjustment raises the total redemption obligation from ₹102.24 crore to ₹109.99 crore.
Key Highlights
Extension of 16,00,000 preference shares redemption period by 1 year to Dec 23, 2026
Redemption price per share revised upward from ₹639 to ₹687.44
Total redemption liability increased from ₹102.24 crore to ₹109.99 crore
Approval of modifications to Material Related Party Transactions with Aditya Birla Capital
👀 What to Watch
The extension preserves immediate cash but increases the eventual payout; investors should watch for the impact on the company's balance sheet in late 2026.
